ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: PUB243

A Unique Case of Hypokalemic Periodic Paralysis with Resolution after Successful Surgery for Cervical Stenosis

Session Information

Category: Fluid, Electrolytes, and Acid-Base Disorders

  • 1102 Fluid, Electrolyte, and Acid-Base Disorders: Clinical

Authors

  • Zaher, Ahmed Abdelnaby Aly Mahmoud, University of California Irvine Nephrology Hypertension & Kidney Transplantation, Orange, California, United States
  • Nguyen, Matthew Duy Thanh Luyen, University of California Irvine Nephrology Hypertension & Kidney Transplantation, Orange, California, United States
  • Hanna, Ramy Magdy, University of California Irvine Nephrology Hypertension & Kidney Transplantation, Orange, California, United States
Introduction

Hypokalemic periodic paralysis is a rare neuromuscular condition that presents with episodic severe muscle weakness, often triggered by strenuous exercise or high carbohydrate diets, that can be further divided into two major types, primary and secondary. The primary type could be genetically inherited or sporadic. The most common mutation causing this condition is CACNA1S gene mutation and the SCN4A gene mutation. The secondary type could be caused by any renal or gastrointestinal pathology causing loss of potassium, along with certain drugs like loop diuretics, thiazide diuretics, laxatives, corticosteroids, beta adrenergic agonists, insulin, and glucose. Here we present a unique case of a 29-year-old white male patient who presented with periodic paralysis attributed to his hypokalemic status.

Case Description

This previously healthy patient did not have any of the secondary causes or any other known condition to cause his periodic paralysis. His serum potassium was between 3.6 to 3.8 mmol/L, and genetic analysis proved that he has a mutation in his CACNA1S gene. Moreover, he has a mutation in 11B-HSD gene causing him to have aberrant mineralocorticoid excess. He reported several episodes of loss of consciousness which is atypical of primary hypokalemic periodic paralysis. Later, after he was treated for cervical stenosis as he was investigated for symptoms of cervical radiculopathy, he reported complete resolution of his symptoms and declines any further episodes of loss of consciousness. At this time, potassium supplements were stopped, given no indication to continue them. However, he was advised to continue to take amiloride if his serum potassium levels dropped below 4 mmol/L.

Discussion

The patient’s clinical presentation is believed to be attributed to his cervical spine lesion instead of his hypokalemic periodic paralysis. More research is required to determine the level of genetic penetrance in each case to customize the treatment accordingly with precision medicine, improving outcomes and minimizing potential adverse effects.